Catalyst stock: buy or sell?

CPRX stock price: $6.62 0.76% At close on September 20th, 2019

Updated on:
September 20th, 2019

3

Shares of Catalyst Pharmaceuticals ended today at $6.62 and stepped up a slightly fine 0.76%. On Sep 12th CPRX collapsed a bloodcurdling -21.21%. On Sep/11 CPRX rocketed an extraordinary 6.86%.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases.

Should I buy Catalyst stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading strategy that matches with your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Catalyst Pharmaceuticals stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Catalyst stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we gathered 2 ratings published for CPRX stock in the last 30 days.

Is CPRX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-8SunTrust Banksn/aBuy
2019-3-19Cantor Fitzgeraldn/aBuy

Catalyst stock analysis

Daily outlook

Catalyst Pharmaceuticals shares stepped up 0.76% to $6.62 today.

On September 11th, CPRX hit new all time highs, pushing higher previous ATH of $7.43 recorded . New ATHs are usual entry points for many trading setups as there aren't higher resistences. Catalyst Pharmaceuticals closed today at $6.62 and stepped up a slightly fine 0.76%. On June CPRX price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since last August/22 when SMA50d and SMA100d crossed up, CPRX price gained $0.35 per share (5.58%).

CPRX stock chart (daily)

Weekly outlook

After sliding a spooky -6.28% in a week last week, Catalyst Pharmaceuticals closed this week at $6.62 and boosted an astounding 6.60%.

Not so far away is the last all-time high Catalyst marked last week. Catalyst stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since mid May when CPRX stock price broke up the SMA40w line, it gained $3.48 (110.83%). Since SMA20d and SMA40w crossed up by mid April, CPRX price climbed $1.23 per share (22.82%).

CPRX stock chart (weekly)

Catalyst stock price history

Catalyst IPO was on November 8th, 2006 at $6.00 per share1. Since then, CPRX stock grew a 10.30%, with an average of 0.90% per year. If you had invested right after CPRX's IPO a $1,000 in Catalyst stock in 2006, it would worth $103.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Catalyst stock historical price chart

CPRX stock reached all-time highs on Sep/11 with a price of $7.67.

Catalyst stock price target is $10.00

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price prediction for Catalyst stock was posted in the last month:
CPRX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-3-19Cantor FitzgeraldReiteratesn/a$10.00-
(in average)$0.00$10.000.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, Catalyst reported its latest financial data, posting a more than good gain for the Earnings per Share (EPS) ratio. Experts were expecting $-0.12 per share, but Catalyst Pharmaceuticals posted $-0.14.
CPRX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.06n/a
2017-Q2-n/a-0.05n/a
2017-Q32017-11-08-0.06-0.05n/a
2017-Q42018-03-14-0.06-0.06n/a
2018-Q12018-05-09-0.06-0.06n/a
2018-Q22018-08-07-0.08-0.06n/a
2018-Q32018-11-07-0.08-0.08n/a
2018-Q42019-03-18-0.12-0.14n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Catalyst annual turnover to $0.50 M dollars from marked in . , its earnings margin (compared to revenues) to -6,800.70%, that is $-34.00 million.

CPRX annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2018$0.50 M-$-34.00 M-6800.7%-

Quarterly financial results

Catalyst reported $0.50 million in revenues for 2018-Q4, a inf% up compared to previous quarter. Reported quarter earnings marked $-14.50 million with a profit margin of -2,899.92%. Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Catalyst Pharmaceuticals sales marked an extraordinary increase and climbed a inf%.
CPRX quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2018-Q4$0.50 M-$-14.50 M-2899.9%-

Catalyst ownership

When you are planning to invest in a stock, it's worth to overview its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Catalyst, 6.89% of all outstanding shares are owned by its staff.

In case of Catalyst Pharmaceuticals stock, 52.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CPRX stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Catalyst:

CPRXABTACORBMRNJNJ
Market cap$681.4 M$147.9 B$167.9 M$13.5 B$343.5 B
Total shares102.9 M1,770.0 M48.1 M179.5 M2,640.0 M
Float shares77.9 M1,750.0 M39.5 M178.3 M2,630.0 M
  - Institutional holdings (%)52.0%76.5%112.3%102.9%69.2%
  - Insider holdings (%)6.9%0.7%1.8%0.4%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Catalyst summary

Friday, September 20th, 2019
Open$6.56
Close$6.62
Day range$6.48 - $6.72
Previous close$6.57
Session gain0.76%
Average true range$0.53
50d mov avg$5.53
100d mov avg$4.67
200d mov avg$4.00
Daily pattern
Weekly pattern lt06a

Catalyst performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Catalyst, the comparison is made against , Acorda Therapeutics, BioMarin Pharmaceutical, , Pfizer and Sarepta Therapeutics.
Stock3m6m12m
CPRXCatalyst Pharmace...84.92%64.68%110.16%
ABT-1.30%8.04%23.06%
ACORAcorda Therapeuti...-53.40%-73.42%-80.82%
BMRNBioMarin Pharmace...-14.74%-14.88%-23.40%
JNJ-7.74%-3.60%-6.42%
PFEPfizer-15.62%-11.17%-14.22%
SRPTSarepta Therapeut...-34.28%-30.18%-42.16%

Catalyst competitors

One check before trading any stock is to have a look a list of its competitors, in this case for Catalyst Pharmaceuticals. We selected 6 companies as Catalyst Pharmaceuticals competitors as they are in the same industry or have similar market objectives.